Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of “Moderate Buy” from Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $55.00.

A number of equities research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, March 13th. Jefferies Financial Group raised shares of Silence Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 18th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Tuesday, April 21st.

Silence Therapeutics Stock Performance

NASDAQ:SLN opened at $6.20 on Friday. The stock has a market cap of $292.89 million, a price-to-earnings ratio of -3.90 and a beta of 1.52. Silence Therapeutics has a 1 year low of $4.19 and a 1 year high of $8.40. The business has a fifty day moving average of $6.55 and a 200-day moving average of $6.10.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Friday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%.The company had revenue of $0.42 million for the quarter, compared to analyst estimates of $1.26 million. On average, equities research analysts predict that Silence Therapeutics will post -1 EPS for the current year.

Institutional Investors Weigh In On Silence Therapeutics

Several large investors have recently made changes to their positions in SLN. EHP Funds Inc. bought a new position in Silence Therapeutics in the third quarter valued at about $55,000. XTX Topco Ltd bought a new position in shares of Silence Therapeutics in the fourth quarter worth about $71,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Silence Therapeutics by 65.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after purchasing an additional 5,421 shares in the last quarter. Massar Capital Management LP acquired a new stake in shares of Silence Therapeutics in the 2nd quarter valued at approximately $115,000. Finally, Citadel Advisors LLC bought a new stake in shares of Silence Therapeutics during the 3rd quarter valued at approximately $112,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.